Dan Marshak

Daniel R. Marshak, Ph.D., is an experienced executive in the Life Sciences, Diagnostics, and Biopharmaceutical industries, leading high-technology, global businesses and R&D functions for more than twenty-five years. Dr. Marshak currently serves as an Independent Director on the Board of Directors for the Tecan Group (SIX:TECN) in Männedorf, Switzerland and on the Board of InVivo Therapeutics (NASDAQ:NVIV), a clinical stage company in Cambridge, Massachusetts focused on spinal cord injury. He also serves as a Director of LifeVault Bio, a private company in Massachusetts. Dr. Marshak is a consultant to several other biotechnology and life sciences companies, as well as to venture capital, investment banking, and private equity firms. Dr. Marshak previously served as Senior Vice President & Chief Scientific Officer for PerkinElmer Inc. (NYSE:PKI) from 2006-2014, where he led global research and development functions. Prior to joining PerkinElmer, Dr. Marshak was Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation (NYSE:CBM.) Dr. Marshak previously served as Senior Vice President and Chief Technology Officer for Osiris Therapeutics, Inc. and was Senior Staff Investigator at the Cold Spring Harbor Laboratory from 1986-1995. Dr. Marshak received his Bachelor of Arts degree in Biochemical Sciences from Harvard University, and holds a Ph.D. in Biochemistry and Cell Biology from The Rockefeller University in New York City. He did postdoctoral work in Pharmacology at the Howard Hughes Medical Institute at Vanderbilt University School of Medicine in Nashville, Tennessee (1983-84) and was a Pharmacology Research Associate Training Fellow at the National Institute of Health in Bethesda, Maryland (1984-86.)Daniel R. Marshak, Ph.D.